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Abstract This review summarizes the characteristics of
the solute carrier family SLC34 that is represented by the
type ll Na/Pi-cotransporters NaPi-lla (SLC34A1), NaPi-
llb (SLC34A2) and NaPi-llc (SLC34A3). Other Na/Pi-
cotransporters are described within the SLC17 and SLC20
families. Type ll Na/Pi-cotransporters are expressed in
several tissues and play a major role in the homeostasis of
inorganic phosphate. In kidney and small intestine, type ll
Na/Pi-cotransporters are located at the apical sites of
epithelial cells and represent the rate limiting steps for
transepithelial movement of phosphate. Physiological and
pathophysiological regulation of renal and small intestinal
epithelial transport of phosphate occurs through alter-
ations in the abundance of type ll Na/Pi-cotransporters.
Keywords Sodium-coupled phosphate transport ·
Type ll Na/Pi-cotransporters · Endocytosis
Introduction
The SLC34 family comprises three members: NaPi-lla,
NaPi-llb and NaPi-llc (Table 1). Non-mammalian family
members have been identified in various organisms such
as flounder and zebra fish, Xenopus laevis, Caenorhab-
ditis elegans, and V. cholerae [42].
Approximately 0.1% of the total content of phosphate
(Pi) in the body is contained in the extracellular space. It
is essential that the extracellular concentration of Pi is
held constant at around 1.1 mM for proper cellular
functions such as DNA formation and signaling reactions,
as well as for bone formation. Members of the SLC34
family are expressed in small intestine and in renal
proximal tubules, two important sites that control the
extracellular concentration of Pi. It should be noted that
extracellular Pi can be influenced by other mechanisms
such as intra- to extracellular shifts (e.g., from skeletal
muscle) which involve other Pi transporters, such as
members of the SLC20 family. In proximal tubules and
enterocytes type ll Na/Pi-cotransporters are located in the
apical membrane and represent the rate limiting steps of
transepithelial Pi transport. In both tissues the abundance
of type ll Na/Pi-cotransporters is controlled by many
hormones and metabolic factors according to the body’s
Pi needs. In kidney, several inherited and acquired
phosphate wasting disorders affect the abundance of type
ll Na/Pi-cotransporters.
Besides the kidney, expression of NaPi-lla has been
described in bone and neurons and in addition to small
intestine, expression of NaPi-llb has been described in a
number of organs such as lung and mammary glands. In
the latter tissues, the detailed physiological and patho-
physiological aspects of the type ll Na/Pi-cotransporters
remain to be defined.
In a physiological environment, all SLC34 family
members exclusively transport phosphate ions in a
obligatory sodium-dependent manner. With the exception
of NaPi-llc, Na/Pi-cotransport is electrogenic. To date, no
specific high-affinity inhibitors are known for this SLC
family; phosphonoformic acid (forscanet) at high con-
centrations (millimolar) inhibits all members. Based on
results obtained from hydropathy analysis, cysteine
scanning mutagenesis and epitope-tagging studies, a
model for the secondary topology of SLC34 transporters
has been proposed.
NaPi-lla (SLC34A1)
This Na/Pi-cotransporter was identified by functional
expression cloning using X. laevis oocytes and a rat and
human kidney cDNA library [30]. The major site of
expression is principally the renal proximal tubule and
here, this protein (80–90 kDa) is localized in microvilli
that constitute the brush border membrane. Under normal
physiological conditions, the abundance of NaPi-lla is
highest in S1 proximal tubular segments of jux-
H. Murer ()) · I. Forster · J. Biber
Institute of Physiology, University of Zrich-Irchel,
Winterthurerstrasse 190, 8057 Zrich, Switzerland
e-mail: hmurer@access.unizh.ch
Tel.: +41-1-6355030/32; Fax: +41-1-6355715
tamedullary nephrons [6]. Three different isoforms of
NaPi-lla have been reported to exist in proximal tubules
as well, yet their function has not been established [39].
Na/Pi cotransport by NaPi-lla is electrogenic, involv-
ing the inward transfer of one net positive charge per
transport cycle. Divalent Pi is the preferred species and is
transported together with three Na+ ions [9, 10]. The
substrates (three Na+ ions and one HPO42 ion) bind in an
ordered manner: Na/Pi/2Na. Typical apparent substrate
affinities are: KmPi ~0.1 mM; KmNa ~70 mM. In the
absence of Pi, the transporter operates in a uniport mode,
whereby Na+ ions leak according to the electrochemical
gradient with a probable stoichiometry of 1 Na+ ion.
Protons interact with the empty carrier and the final Na-
binding steps. Higher transport rates are observed at more
basic external pH values [10]. Dependency on pH has
partially been conferred to the charged amino acid motif
(REK) contained in the putative extracellular loop ECL3
[7] (Fig. 1).
NaPi-llb (SLC34A2)
NaPi-llb was identified based on EST clones derived from
lung tissue [8, 16]. Expression of NaPi-llb mRNA has
been detected in a number of tissues such as small
intestine, lung, mammary glands, testis, and liver [43]. By
immunofluorescence, NaPi-llb was localized in brush
borders of enterocytes, in the apical pole of alveolar type
Fig. 1 Secondary topology of the NaPi-lla (SLC34A1) based on
current structure-function studies [9]. The protein comprises eight
transmembrane domains (TMD1–8) with intracellular N- and C-
termini and a large extracellular loop (ECL-2) containing two N-
glycosylation sites (hexagons). An essential disulphide bridge in
ECL-2 links each complementary part to form the functional unit.
Cysteine scanning mutagenesis has revealed functionally important
residues at sites indicated (open squares). Two reentrant loops
(ICL-1, ECL-3) are predicted to associate and form the transmem-
brane cotransport pathway. In ECL-3, proline-461 terminates a 2.5
turn a-helix motif (boxed) thought to be an essential part of this
pathway, while in ICL-1 asparagine-199 is a critical determinant of
transport mode. A triad of three adjacent charge residues (R462,
E463, K464) in ECL-3 confers part of SLC34 proton sensitivity
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ll cells as well as in apical membranes of mammary
secretory cells [16, 31, 41]. On Western blots, fully
glycosylated NaPi-llb is observed as a band of approx-
imately 108 kDa [16]. Interestingly, in weaning animals
NaPi-llb was reported to be only partially glycosylated
[1].
At the primary sequence level NaPi-llb differs from
NaPi-lla mainly in the C-terminus, which is rich in Cys
residues and longer by approximately 50 amino acids. Na/
Pi-cotransport is also electrogenic with a likely stoichi-
ometry of 3Na:1Pi and with KmPi<50 mM and
KmNa=40 mM. Dependence on pH is moderate, slightly
higher cotransport is observed at more acidic pH [16].
NaPi-llc (SLC34A3)
This member was identified based on human EST clones.
Expression of NaPi-llc was found exclusively in kidney
and was described as being growth related. The protein
(75 kDa) was localized in apical membranes of proximal
tubules of deep nephrons. Na/Pi-cotransport by NaPi-llc is
electroneutral (KmPi=70 mM; KmNa=50 mM) and is highly
pH dependent, exhibiting higher transport at more alka-
line pH [36].
Structural aspects of type ll Na/Pi-cotransporters
As predicted from structure-function studies [10, 26],
each type ll Na/Pi-cotransporter protein most likely spans
the membrane eight times. Both N- and C-termini are
located cytoplasmatically and there are multiple N-
glycosylation sites in a large extracellular loop. Further-
more, two short (extracellular and intracellular) loops
have been postulated to be important functional regions
for the transport pathway [10, 24]. A model of the
secondary structure of SLC34 Na/Pi-cotransporters is
depicted in Fig. 1. This model is based on data obtained
with NaPi-lla (SLC34A1), but appears to be valid for the
other family members as well, since in all members, the
transmembranous regions are over 80% identical and
exhibit the same hydropathy profile [10]. The largest
dissimilarities are found in the N- and C-termini and in
the large extracellular loops. Based on results obtained
with tandem constructs of NaPi-lla, it is assumed that the
monomeric form is sufficient for full type ll-mediated Na/
Pi cotransport [23].
Physiological, pathological
and pharmaceutical aspects
The concentration of the extracellular Pi is controlled by
the body’s need, and in adults it is kept constant at around
1.1 mM. This is achieved largely by a control of the renal
capacity to reabsorb Pi from the primary urine and, to a
lesser extent, by a control of small intestinal absorption of
Pi (see below). Expression of SLC34 members was also
described in other tissues such as bone [13], brain [17],
mammary glands [31], and lung [8, 41] (Fig. 2); however,
the physiological roles of type ll Na/Pi-cotransporters
described at these sites have not yet been entirely defined.
In type ll alveolar cells, NaPi-llb was localized in the
apical membrane and may be involved in the reabsorption
of Pi contained in the surfactant. In secreting mammary
glands, a role of NaPi-llb could be envisaged in delivering
Pi into milk during lactation.
SLC34A1 and SLC34A3 and renal reabsorption
of phosphate
The importance of NaPi-lla in the renal handling of Pi was
demonstrated by a Npt2 knock out mouse [4]. Npt2/
mice exhibit severe hypophosphatemia that is explained
by an approximately 70% decrease of brush-border
membrane Na/Pi cotransport. The remaining Na/Pi co-
transport activity has been attributed to NaPi-llc.
Both NaPi-lla and NaPi-llc are targets for the adjust-
ment of renal reabsorption of Pi and are regulated by
many different hormones (e.g., parathyroid hormone) and
metabolic factors (e.g., Pi diet or acidosis) [33, 36, 38].
Furthermore, factors derived from tumors associated with
osteomalacia (e.g., FGF23) have been implicated to
regulate NaPi-lla in proximal tubules [11, 25, 40].
Regulation of proximal tubular reabsorption of Pi was
described as being due to an alteration of the abundance
of NaPi-lla or NaPi-llc proteins residing in the brush-
border membrane. It is assumed that at a constant rate of
the de-novo synthesis, the amount of NaPi-lla is altered
by regulated endocytosis [33]; so far, no such mechanism
has been reported for NaPi-llc. In contrast to other
regulated membrane transport processes, internalized
NaPi-lla proteins do not recycle, but undergo lysosomal
degradation [20, 28, 34]. Although many aspects of the
Fig. 2 Sites of expression of type ll Na/Pi-cotransporters (SLC34).
Whereas the roles of NaPi-lla and NaPi-llb in epithelia of renal
proximal tubules and small intestine are well described (see text for
references) the roles of SLC34 cotransporters in other tissues
(indicated in boxes) are less well defined
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signaling cascades, such as the involvement of cAMP and
cGMP and different protein kinases have been described
[2, 3, 33], neither the precise mechanisms of the
internalization of NaPi-lla nor the mechanisms involved
in the vesicular trafficking of internalized NaPi-lla
proteins have been defined. With respect to hormone-
mediated endocytosis of NaPi-lla, a dibasic amino acid
motif (RK) within the putative intracellular loop ICL3
was shown to be important as after mutations at this site
NaPi-lla was no longer responsive to parathyroid hor-
mone [18].
Acute (2–4 h) and chronic (days to weeks) Pi depletion
has been shown to increase the level of NaPi-lla [21, 27].
In case of chronic Pi depletion a posttranscriptional
mechanism has been suggested involving –Pi renal
proteins to stabilize NaPi-lla mRNA [32].
Recent data have demonstrated that in renal proximal
cells, NaPi-lla interacts with the PDZ proteins NHERF-1
and PDZK1 [12]. Such interactions appear to be impor-
tant for correct apical sorting and or positioning of NaPi-
lla, as shown by a NHERF-1 knock out model [37] and by
studies in OK cells [15]. On the other hand, PDZK1/
mice do not show any changes of NaPi-lla content,
suggesting a possible redundancy of other PDZ interac-
tions [22].
Several renal wasting disorders have been described
that are based on changes of the expression of NaPi-lla
[40]. Studies related to the inherited disorders XLH (X-
linked hypophosphatemia) and ADHR (autosomal dom-
inant hypophosphatemic rickets) and studies related to the
acquired disorder OHO (oncogenic hypophosphatemic
osteomalacia) revealed evidence that the two genes PHEX
and FGF23 play important roles in determining the
abundance of NaPi-lla in renal proximal tubules [11, 25,
40]. Recently, two naturally occurring mutants of NaPi-lla
(positions 48 and 147) have been identified and linked to
two cases of renal wasting disorders of phosphate [35].
SLC34A2 and intestinal absorption of phosphate
Several observations provided evidence that NaPi-llb is
involved in transcellular flux of phosphate in small
intestine [14, 16, 19, 44]. Therefore small intestinal NaPi-
llb could represent a possible target for treatment of
hyperphosphatemia as often observed in dialysis patients.
The most prominent regulators of NaPi-llb in small
intestine are 1,25-(OH)2-vitaminD3 and low-phosphate
diet. Upregulation of NaPi-llb induced by these factors is
manifested by an increase of the protein abundance and
appears, in adults, to be nontranscriptional [14, 19, 44].
Furthermore, regulation of NaPi-llb in small intestine by
EGF [43], glucocorticoids [1], thyroid hormone [5], and
stanniocalcin l [29] has been reported.
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